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1. Introduction 
In the United States, 22020 new cases of cancer in central nervous system (CNS) are 
expected to occur in 2010 (CBTRUS 2010). Although the incidence of cancers in CNS is much 
lower than that of malignancies in other organs such as lung, breast and colorectal cancers, 
CNS cancers are the second lethal cancer for males younger than 40 years (Jemal et al. 2010). 
In addition, with the unconstraint growth, brain cancers can often involve eloquent area. As 
a result, the neurological and psychological deficits may severely damage the health-related 
quality of life (QOL) in patients with brain cancers. Improvement of QOL and the prognosis 
of brain cancers is the goal of both physicians and basic investigators.  
Glioblastoma multiforme (GBM) is the most frequent primary brain cancer, accounting for 
17% of all primary tumours in CNS. In the past five decades, despite the advances in the 
fields of neurosurgery, radiotherapy and pharmaceutics, the prognosis of patients with 
GBM remains dismal, with a 5-year survival of only 9.8%(Stupp et al. 2009). The nature of 
extensive proliferation, diffuse infiltration and resistance to conventional treatments makes 
the chance to cure GBM slim. Exploration of mechanisms underlying therapeutic resistance 
of GBM and developing novel strategies against GBM are of urgent necessity. 
The emergence of brain tumour stem cell (BTSC) theory is a great breakthrough in the field 
of neuro-oncology. BTSC theory assumes that brain tumour is a hierarchy of cancer cells 
maintained by a small population of cells sharing characteristics of normal embryonic and 
somatic stem cells. BTSC theory is confirmed by the isolation of BTSCs from established 
brain tumour cell lines and freshly surgical samples. Accumulated evidence suggests that 
BTSCs are responsible for the initiation, progression, recurrence and treatment resistance. 
Therefore, BTSCs are promising therapeutic targets. In this chapter, we aim to summarize 
advances in BTSC biology with the focus on the treatment strategies against BTSCs. 
2. Identification of BTSCs 
The hypothesis that tumours arise from cancer stem cells (CSCs) is not new. The histological 
similarity between cancers and embryonic tissues was observed by Rudolph Virchow more 
than one century ago (Huntly and Gilliland 2005). The heterogeneity of cancer and only a 
small cancer population capable of forming clones in vitro and reconstituting tumour in vivo 
have also been wildly recognized for decades. However, because of the limitation of 
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knowledge and technology in molecular biology, CSCs have not been confirmed in 
leukemia and solid tumours including brain tumours until late 1990’s (Clevers 2011). 
2.1 Isolation and characterization of BTSCs 
In 2002, based on the finding that the expression of markers specific for undifferentiated 
neural cells was detected in malignant glial tumours, Ignatova and coworkers assumed the 
existence of cells sharing features of normal neural stem cells (NSCs) in gliomas (Ignatova et 
al. 2002). By using in vitro serum-free NSC culture system supplemented with epidermal 
growth factor (EGF) and fibroblast growth factor (FGF), the authors successfully isolated 
NSC-like cells from human glioma tissues. These cells are capable of forming clones 
morphologically resembling those generated by NSCs. And populations from the tumour-
derived clones demonstrate positive for NSC marker nestin, differentiated neuronal marker 
β-III tubulin or glial lineage-specific marker glial fibrillary acidic protein (GFAP). Singh and 
coworkers confirmed the existence of BTSCs and did further feature analysis (Singh et al. 
2004). Their investigation demonstrated that CD133-positive tumour cells in gliomas possess 
obvious stem cell characterization of extensive proliferation, self-renewal and lineage-
restricted differentiation that recapitulates the original tumour phenotype. In addition, the 
CD133-positive tumour cells show a strong ability to form tumours in xenograft models. 
One hundred CD133-positive glioma cells efficiently initiate tumours in immunocompromised 
mice while 100,000 CD133-negative glioma cells fail to establish tumours. The BTSC model 
appears to be more robust in preclinical research than traditional established cell lines kept 
in serum-containing medium, because the former has been shown to mirror both the 
phenotype and genotype of their parental tumours (Lee et al. 2006). With transcriptome 
analysis, Fine’s group found that GBM cells maintained in serum-free NSC media have gene 
expression profiles similar to NSCs and harbour all the genetic aberrations detected in 
primary tumours. Genetic stability maintains even after repeated passage. Moreover, these 
NSC-like glioma cells demonstrate a high tumourigenic potential and establish tumours 
with extensive infiltration into normal brain in vivo, which is frequently observed in human 
GBMs. By contrast, GBM cells under standard in vitro conditions with serum-containing 
media, undergo dramatic de novo genomic rearrangement over time, with a divergence from 
genotype of parental GBMs but displaying resemblance to genomic features with commonly 
used glioma cell lines. A majority of these cells lose the ability to initiate tumours in murine 
models. Even for a small subset of glioma cells that retain tumourigenic potential, the 
xenografts they generate phenotypically differ from their parental human GBMs. 
Collectively, BTSCs are defined as a small population in brain tumours, with the ability to 
maintain the BTSC pool by self-renewal and with the ability to extensively proliferate into 
differentiated non-tumourigenic brain tumour cell phenotypes that reconstitute the cellular 
heterogeneity of the parental brain tumours.  
2.2 Identification of BTSCs 
2.2.1 CD133 
Human CD133, also known as prominin-1, is a pentaspan transmembrane glycoprotein 
localized in membrane protrusions, which contains 865 amino acids with a nonglycosylated 
molecular weight of 97 kDa. The predicted structure of CD133 composes an 85-amino acid 
N-terminal extracellular domain, five transmembrane domains with two large extracellular 
loops containing eight potential N-linked glycosylation sites, and a 50-amino acid cytoplasmic 
tail. It was first identified as a hematopoietic stem cell antigen (Miraglia et al. 1997). 
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Although CD133 mRNA is found to be strongly expressed in multiple organs including 
adult kidney, trachea and digestive tract, glycosylation immunoreactivity of CD133 appears 
to be restricted to undifferentiated cell types and reduce during differentiation (Florek et al. 
2005; Corbeil et al. 2000). Subsequently, CD133 has been demonstrated to be successfully 
used as a marker to define and purify stem and progenitor cell populations in various 
organs such as fetal liver, kidney, prostate and brain (Rountree et al. 2007; Angelotti et al. 
2010 ; Vander Griend et al. 2008 ; Barraud et al. 2007).  
Because the resemblance of cancer stem cells to normal stem cells, CD133 is also widely 
employed as a marker to identify and isolate cancer stem cells in multiple solid tumours 
such as prostate cancer, colon cancer and melanoma (Collins et al. 2005, O'Brien et al. 2007; 
Monzani et al. 2007). In addition, the clinical relevance of CD133 expression with the 
prognosis of brain tumour patients and the association of CD133 immunoreactivity with 
BTSCs are well documented. The proportion of CD133-postive cells in WHO grade 2 and 3 
gliomas is found to be an independent risk factor for tumour recurrence and time to 
malignant progression (Zeppernick et al. 2008). Consistently, the presence of CD133 has 
been demonstrated to be correlated with a decreased survival in patients with high-grade 
oligodendroglial tumours (Beier et al. 2008). Preclinical studies demonstrated that the 
CD133-positive BTSCs are capable of extensive self-renewal and recapitulation of original 
tumours. Moreover, ectopic overexpression of CD133 in rat C6 glioma cells significantly 
enhances the chemoresistance of tumour cells to camptothecin and doxorubicin. Tumour 
cells with increased expression of CD133 appear to be more reluctant to undergo apoptosis 
after the treatment of cytotoxic agents, which is demonstrated as a result of elevated efflux 
of drugs by up-regulating ATP-binding cassette transporters ABCB1 (Angelastro and Lame 
2010). The studies aforementioned suggest CD133 as a bona fide marker for BTSCs. However, 
the emergence of conflicting evidences indicates that CD133 is not necessarily required for 
BTSC phenotype. The existence of CD133-negative BTSCs is confirmed as well. It has been 
shown that a hierarchy of self-renewing BTSC types exists in GBMs. Both CD133-positive 
and CD133-negative glioma cells in individual GBMs exhibit self-renewal in vitro and 
initiate highly aggressive tumours in vivo. Notably, CD133-negative glioma cells can even 
give rise to CD133-postive cells (Chen et al. 2010). Moreover, CD133 expression has been 
proposed as an indicator of bioenergetic stress rather than to be obligatorily related with 
BTSC phenotype in human gliomas. Reduced oxygen levels have been shown to increase the 
CD133 expression in gliomas (Bar et al. 2010). Mitochondrial dysfunction can also up-
regulate CD133 expression that is inversely correlated with changes in mitochondrial 
membrane potential. Genetic depletion of mitochondrial DNA results in a remarkable 
increase of CD133 expression, which can be reversed by re-introducing parental 
mitochondria (Griguer et al. 2008).  
To reconcile the discrepancies in the CD133 studies, several hypotheses are proposed. First, 
the limitations of current antibodies against epitopes of CD133 can lead to inconsistent 
results. AC133 and AC141 mAb, reported to bind the extracellular glycosylation epitope of 
CD133, are the most commonly used antibodies to identify and purify BTSCs. However, 
little is known about the molecular nature of the epitopes recognized by these two 
antibodies. Although AC133 and AC141 mAbs are sometimes used interchangeably, 
discordant results about the expression of the AC133 and AC141 epitopes were observed in 
other cancer stem cell types (Green et al. 1999). Additionally, the presence of alternatively 
spliced CD133 isoforms is another complicating factor. Transcription of CD133 can be 
started at five tissue-restricted promoters, producing several alternatively spliced transcripts, 
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among which there are possible spliced isoforms without AC133 and AC141 epitopes. In 
this case, some BTSCs are actually CD133 false negative. Secondly, BTSC phenotypes that 
are independent of CD133 status may exist. Several lines of evidence support this hypothesis. 
With genetic approach, BTSC population depleted of CD133 was generated. BTSCs lacking 
CD133 expression can proliferate as tumour-spheres in vitro and produce gliomas when 
transplanted into mouse brain, indicating the dispensable role of CD133 in BTSC maintenance 
and gliomagenesis (Nishide et al. 2009). In addition, transcriptional profiles demonstrated a 
distinct gene expression in CD133-positive BTSCs compared to CD133-negative BTSCs. 
CD133-positive BTSCs, growing as neurospheres, display “proneural” transcriptional 
profiles with a resemblance to fetal neural stem cells, while CD133-negative BTSCs with a 
semiadherent/adherent growth pattern show “mesenchymal” signature genes similar to 
adult neural stem cells. The molecular heterogeneity of CD133-positive and –negative 
BTSCs implied the different origins of these two BTSC populations (Lottaz et al. 2010).  
2.2.2 Side population technique 
Side population (SP) cells are referred to a small population of cells which are capable of 
excluding vital dye Hoechst 33342 and featured in flow cytometry plots as the “side” of the 
bulk of positively labeled cells. The exclusion of Hoechst 33342 by SP cells has been 
suggested as a result of the cells’ ability to pump out drugs mediated by ABCG2, an ATP-
binding cassette (ABC) transporter (Scharenberg, Harkey, and Torok-Storb 2002). SP cells 
were first identified in mouse bone marrow, with the enrichment of stem cell properties. The 
observations that SP cells share stem cell features have been extended in other normal and 
tumour tissues. In glioma, SP cells demonstrate characteristics of pluripotency in vitro and 
high tumourigenicity in vivo. Kondo and coworkers successfully isolated SP cells from the 
rat glioma cell line C6, which only account for 0.4% of the cells maintained in serum-
containing medium. C6 SP cells can form neurospheres in culture free of serum and produce 
SP as well as non-SP cells in vitro. Moreover, C6 SP cells are capable to initiate tumours 
containing multiple lineages such as neurons and glia when transplanted into various 
tissues in nude mice (Kondo, Setoguchi, and Taga 2004). In addition, SP cells have also been 
associated with the resistance to anti-cancer treatment. When exposed to temozolomide 
(TMZ) at DNA-damaging dose, SP cells purified from astrocytoma cell lines demonstrate a 
profound resistance to the cell arresting effects of the drug and maintain a robust 
proliferative capacity, compared with non-SP cells. The percentage of SP cells increases as 
high as 8-fold (Chua et al. 2008). Consistently in a platelet-derived growth factor (PDGF)-
induced glioma mouse model, SP cells are shown to be less sensitive to TMZ relative to non-
SP cells. Moreover, the in vivo aggressiveness of SP cells increases greatly after treatment 
with TMZ. Mechanistically, an increased level of O6-methylguanine-DNA methyltransferase 
(MGMT) in SP cells contributes to the chemoresistance to TMZ (Bleau et al. 2009). 
Although SP technique is effective in enriching BTSCs, there is disagreement regarding the 
connection between SP and BTSC phenotypes. As mentioned above, only a small fraction of 
C6 glioma cells (0.4%), namely, SP cells, fulfill the criteria of BTSCs. However in a study 
using clonal and population analyses, Zheng and coworkers revealed that most single C6 
cells have similar clone formation ability in vitro and tumourigenic potential in vivo, 
suggesting that most of C6 glioma cells are BTSCs. Furthermore, Hoechst 33342 is shown 
cytotoxic and can impair the clonogenicity and proliferation of individual C6 cells. The 
authors therefore postulated that Hoechst 33342 labeling and sorting can deprive non-SP 
cells of their stemness (Zheng et al. 2007). In addition, Srivastava and coworkers 
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demonstrated that both the SP and non-SP fraction in medulloblastoma can produce 
neurospheres and regenerate both fractions. The toxicity of Hoechst 33342 to medulloblastoma 
cells, especially non-SP cells, is also confirmed in this study and suggested as the reason for 
the biological differences between SP and non-SP fractions (Srivastava and Nalbantoglu 
2008).  
Collectively, CD133 and SP technique are successful in the identification and purification of 
BTSCs. However, these two approaches are unlikely to be enough to define all BTSC 
phenotypes because of their intrinsic limitations and the complexity of BTSCs. As a result, 
cautions should be exerted in interpreting results generated with these two methods. The 
development of novel approaches to enrich BTSCs is also critical. 
2.3 Maintenance and expansion of BTSCs in vitro 
The establishment of models in which BTSCs can be properly propagated is critical for the 
studies of BTSCs. To date, neurosphere culture is the most commonly used protocol to 
expand BTSCs. According to this protocol which was first developed by Reynolds and 
Weiss for neural stem cell studies, BTSCs are cultured in serum-free medium supplemented 
with growth factors, for example, EGF and FGF. Under this condition, BTSCs grow as 
floating aggregates with extensive self-renewal (Reynolds and Weiss 1992; Galli et al. 2004). 
When transferred to medium with serum, these cells differentiate and express neuron and 
glia markers. Notably, BTSCs maintained as neurospheres are highly tumourigenic and 
initiate tumours with phenotypical and genetical resemblance to their origins. Neurosphere 
culture successfully maintains the BTSC phenotype and is therefore widely used to explore 
key issues in BTSC biology. However, several studies call into question neurosphere culture 
as a reliable method to expand and analyze BTSCs. First, neurosphere culture protocol has a 
low efficiency to establish BTSC lines (Laks et al. 2009). Secondly, the majority of cells in 
neurospheres are more differentiated and/or dying progeny (Martens, Tropepe, and van 
Der Kooy 2000). Thirdly, the aggregating growth manner of BTSCs and the fuse between 
neurospheres make the evaluation of the efficacy of treatment difficult (Woolard and Fine 
2009). In order to overcome the limitations of neurosphere culture, novel methodological 
approaches have been investigated, among which the adherent culture developed by 
Pollard and coworkers is of great promise (Pollard et al. 2009). With this adherent culture, 
tumour cells from surgical glioma tissues are maintained and passaged in laminin-coated 
flask with neural stem cell medium. BTSC phenotypes are retained under this condition, 
harbouring genetic aberrations consistent with parental tumours. The efficiency of 
successful establishment of BTSC lines is 100% for adherent culture but is only around 
30% for neurosphere culture. In addition, the adherent population composes more true 
BTSCs compared with neurosphere culture, because of less differentiation and apoptosis. 
Furthermore, the adherent monolayer growth pattern of BTSCs is more suitable for 
chemical screens. Therefore, adherent culture appears to be superior in the maintenance of 
BTSCs. 
2.4 Animal models for BTSCs 
Although the in vitro culture protocol offers a convenient and less expensive method to 
maintain BTSCs, it has apparent limitations. Most of all, the in vitro culture is unable to 
establish a specific and interactive microenvironment as BTSCs have in brain tumour tissues 
(Sanai, Alvarez-Buylla, and Berger 2005). As a result, BTSCs may undergo genotypic and/or 
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phenotypic changes so as to adapt to the in vitro environment, which potentially weakens 
the clinical relevance of BTSCs, especially when to test the efficacy of novel chemotherapeutic 
drugs and small molecule inhibitors.  
In order to overcome the drawbacks of the in vitro culture systems, different categories of in 
vivo animal models were developed to maintain BTSCs and were employed to dissect the 
molecular events in BTSCs. Transgenic murine model is one of them. In this model, mouse 
lines genetically engineered with specific genetic alterations frequently observed in human 
brain tumours were created. Notably, with the advances in genetic techniques, the gain and 
loss of one or multiple genes can be conditionally manipulated in a tissue- and/or time-
specific manner. For instance, tet-regulated or CRE-inducible alleles of genes can allow for 
the control of the timing, duration, and tissue compartment of gene expression or 
inactivation (Glaser, Anastassiadis, and Stewart 2005). The spontaneous brain tumours 
generated from these transgenic murine models are appropriate resources of BTSCs. In a 
S100β-verbB;Trp53 transgenic murine model that develops spontaneous gliomas, the 
existence of BTSCs was confirmed, which were enriched in the side-population cells and 
characterized with self-renewal, multipotentiality and enhanced tumour-initiating capacity 
(Harris et al. 2008). Similarly, Ward and coworkers harvested BTSCs from medulloblastomas 
arising from genetically engineered Patched-1-deficient mice. These BTSCs displayed a 
neural precursor phenotype and were capable to generate medulloblastomas following 
allogeneic orthotopic transplantation (Ward et al. 2009).  
Besides, transgenic murine models provide valuable information on fundamental and 
mechanistic facets of BTSC biology. Until now, amounting evidences supports the role of 
BTSCs in the tumourigenesis of brain tumours. But questions are coming with the BTSC 
theory. Among them, where BTSCs originate is the most intriguing one. Three hypotheses 
on the origin of BTSCs are proposed: (1) mature astrocytes dedifferentiate to have stem cell-
like properties, (2) committed progenitors acquire mutations that endow them with 
unstrained “stemness”, (3) neural stem cells become tumourigenic as a result of the chaotic 
regulation in mitosis and differentiation. Physiologically relevant transgenic murine models 
that spontaneously generate gliomas provide an ideal and powerful approach to tackle this 
question. Studies with somatic cell mouse models demonstrated that the loss function of 
pivotal tumour suppressor genes render early cortical astrocytes susceptible to oncogenic 
transformation and dedifferentiate to initiate gliomas, suggesting the possibility of the 
reprogrammed astrocytes as the precursors of BTSCs (Uhrbom et al. 2005, ; Xiao et al. 2005). 
Committed progenitors have also been shown to be able to derive BTSCs. Overexpression of 
oncogenic HRasL61 in p53-deficient oligodendrocyte precursor cells (OPCs) can result in the 
generation of BTSCs in mice (Hide et al. 2011). By using RAS/tv-a mouse model, Lindberg 
and coworkers specifically transferred PDGF-B into OPCs and successfully induced gliomas 
in vivo. The introduction of PDGF-B resulted in the expression of SOX2, OLIG2 and NG2 in 
tumour cells, implying a slight dedifferentiation of the targeted OPCs (Lindberg et al. 2009). 
Because of the similarities that BTSCs share with neural stem cells, it is logical to assume 
that BTSCs may derive from neural stem cells. Clinical and genetic studies provide clues 
that some GBMs may arise from the subventricular zone where neural stem cells originate. 
Wang and coworkers employed a transgenic murine model with an in-frame p53 deletion 
mutation specially targeted into the nervous system to investigate the role of neural stem 
cells in p53-mediated gliomagenesis (Wang et al. 2009). This study revealed that p53 
deficiency provides no significant growth advantage to adult brain cells, but can induce 
accumulation of cooperative oncogenic alterations in neural stem cells in subventricular 
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zone and subsequently result in glioma formation in experimental animals, which links 
BTSCs with neural stem cells. In addition, neural stem cells derived from mice with 
concomitant specific deletion of p53 and Pten in the central nervous system have an 
enhanced self-renewal and impaired differentiation and initiated acute-onset infiltrative 
high-grade gliomas (Zheng et al. 2008). The oncogenic transformation of neural stem cells is 
demonstrated to be driven by the up-regulation of Myc protein.  
As mentioned above, transgenic murine models shed light on the initiation of BTSCs and 
play an important role in the studies to analyze the functionality of specific genes and 
cooperative gene networks in BTSCs. But there are ongoing concerns about transgenic 
murine models: (1) targeting selected genes in transgenic these models are not likely to fully 
replicate the clinical and biological heterogeneities of brain tumours, (2) the mouse-derived 
brain tumours may biologically divert from human counterparts because of species 
difference.  
Xenograft model is another option to investigate BTSCs. In this model, human glioma tissue 
or cells that enrich BTSCs are implanted heterotypically (in nonautochthonous site) or 
orthotopically (in the original site) in immunodeficient animals. Although heterotypical 
subcutaneous xenograft model is widely used to investigate brain tumours, subcutaneous 
implantation of GBM cells has been shown to generate tumours with less clinical relevance 
because organ-specific environment plays a vital role in glioma behaviour (Antunes et al. 
2000). Therefore, orthotopic intracranial xenograft models appear to be superior in the 
preclinical studies of brain tumours and BTSCs. Orthotopic xenograft models of multiple 
brain tumour types such as GBM, medulloblastoma and ependymoma have been 
successfully established. The tumours generated from these models bear histopathological 
resemblance to their origins and BTSCs can be isolated from the orthotopic models (Fei et al. 
2010 ; Shu et al. 2008,; Yu et al. 2010). Because of the advantage to faithfully recapitulate the 
biological phenotypes of original patient tumours and stably preserve BTSC pool, the 
orthotopic model is an optional approach to facilitate biological studies of BTSCs. In 
addition, novel therapeutic strategies such as telomerase angtagonist, oncolytic picornavirus 
and Akt inhibitors have been pre-clinically tested in orthotopic xenograft models and yield 
promising outcomes by preferentially targeting BTSCs (Marian et al. 2010; Yu et al. 2011; 
Eyler et al. 2008).  
3. BTSC, the prime culprit for treatment resistance 
The identification of BTSCs provides insight into the therapeutic resistance of brain tumours 
and lead to a reassessment of current treatment against brain tumours. Most of current 
therapies have the power of mass destruction against the non-BTSC population but fail to 
precisely strike BTSCs.  
3.1 Radioresistance 
Radiotherapy is a mainstay in the management of GBMs and eliminates glioma cells mainly 
through inducing a DNA double-strand break. Although effective, radiotherapy can seldom 
eradicate all the glioma cells and the recurrence of GBM after radiotherapy seems inevitable. 
A growing body of evidence supports that BTSCs play a pivotal role in the resistance of 
radiotherapy. With magnetic resonance (MR) imaging and L-[methyl-11C] methionine 
positron emission tomography (MET-PET) scanning, Taumura and coworkers demonstrated 
that most of malignant gliomas treated with Gamma Knife surgery (GKS) plus external 
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beam radiation (EBRT) recur even with initially well responding. Malignant glioma cells are 
found within the areas exposed to irradiation. In histological sections after GKS plus EBRT, 
CD133-positive tumour cells markedly accumulate while are infrequent in primary sections 
obtained before irradiation. These CD133-positive glioma cells are postulated as BTSCs and 
are capable of surviving high dose irradiation (Tamura et al. 2010).  
The radioresistance of BTSCs may stem from an increase in DNA repair. After irradiation, 
CD133-positive BTSCs are enriched because of their capability to preferentially activate the 
DNA damage checkpoint and repair radiation-induced DNA damage more efficiently than 
those CD133-negative non-BTSCs. The radioresistance of CD133-positive BTSCs can be 
reversed with a specific inhibitor of Chk1 and Chk2 cell cycle checkpoint kinases (Bao et al. 
2006). In addition, autophagy has been shown to contribute to the radioresistance of BTSCs. 
Autophagy is a process of self-cannibalization whereby cells maintain homeostasis and 
survive under stress via lysosomal degradation of cytoplasmic proteins and organelles. In a 
study carried out by Lomonaco and coworkers, the expression of autophagy-related 
proteins, such as LC3, ATG5 and ATG12, are found higher in CD133-positive BTSCs 
compared with CD133-negative cells. Gamma-radiation induces a larger degree of 
autophagy in CD133-positive BTSCs. Autophagy protects cancer cells from radiation 
damage by decreasing cytoplasmic acidification, by providing catabolites required for DNA 
repair and by removing toxic substances. Inhibition of autophagy can significantly decrease 
the viability of BTSCs in response to γ-radiation (Lomonaco et al. 2009). The mechanism 
underlying the induction of autophagy in BTSCs by γ-radiation is not elucidated. But recent 
studies suggested that the activation of ataxia-telangiectasia-mutated (ATM), a checkpoint 
protein, following radiation, can lead to an inhibition of mTOR pathway through the 
phosphorylation of LKB-1, which may initiate the process of autophagy. The role and the 
mechanism of autophagy in the radioresistance of BTSCs still need further investigation.  
More recently, the microenvironment that BTSCs reside in has been found to contribute to 
the radioresistance of GBM (Jamal et al. 2010). When intracranially transplanted, BTSCs 
demonstrate a less susceptible to irradiation and have a faster repair of radiation-induced 
DNA damage reflected by the dispersal of γH2AX foci, compared with their counterpart 
grown in vitro. Microarray analysis revealed that genes involved in reactive oxygen species 
(ROS) scavenging and antioxidant response are significantly influenced in BTSCs in 
xenografts, which appears to subsequently render BTSCs to be more resistant to 
radiotherapy in vivo. 
3.2 Chemoresistance 
GBMs are notorious for their insensitivity to chemotherapeutic agents. Recently, BTSCs have 
been demonstrated to be involved in the chemoresistance of GBMs. In vitro, BTSCs isolated 
and cultured from surgical GBM specimens display marked resistance to cytotoxic drugs 
including TMZ, cisplatin, epotoside and vincristine. BTSCs can recover and proliferate 
quickly following treatment with antineoplastic agents (Eramo et al. 2006). Moreover, 
glioma cells isolated from multiple tumour areas have different sensitivity to TMZ. More 
committed glioma cells are found to distribute along the peripheral area and to undergo 
apoptosis in response to TMZ, while more immature cells with CD133 positivity localized in 
the inner core of GBMs and are more insensitive to TMZ (Pistollato et al. 2010). Gene 
expression analysis of GBM patients treated with concomitant chemotherapy with TMZ 
revealed that an expression gene set comprising CD133 is associated with treatment-
resistance and predicts poor survival in this group of patients. Intriguingly, the gene set 
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includes a cluster that is reminiscent of a self-renewal gene signature identified in murine 
MLL-AF9-induced leukemic stem cells derived from committed progenitors, which suggests 
the relevance of a stem-like cell phenotype in the treatment resistance of GBMs (Murat et al. 
2008). Pallini and coworkers conducted a prospective investigation to explore the prognostic 
potential of in vitro BTSC analysis and the presence of CD133-positive cells in 44 consecutive 
GBM patients treated with concurrent chemoradiation followed by TMZ. Fourteen GBMs 
which can generate BTSC in vitro have a less favourable prognosis, with a median overall 
survival of 8 months compared with 14 months among GBMs without generation of BTSCs. 
In addition, the presence of more than 2% CD133-positive cells in GBM lesions is associated 
with an early progression. The median progression-free survival is 10 months for GBM 
patients with less than 2% CD133-positive cells while it was only 5 months for those with 
more than 2% CD133-positive cells (Pallini et al. 2008). Similarly, the prognostic value of the 
presence of BTSCs and CD133 expression is also shown in high-grade oligodendroglial 
tumours treated with chemotherapy. Patients with tumours neither containing BTSCs nor 
showing CD133 expression have a favourable clinical outcome. In this study, the possibility 
of presence of CD133 vascular progenitor cells is excluded with immunohistochemical 
double staining of CD133 and the panvascular marker CD31. Weakly double-positive cells 
for CD133 and CD31 are only detected in one of 20 tumours investigated, which indicates 
that the CD133-positive cells are derived from tumours instead of vasculatures (Beier et al. 
2008).  
BTSCS have been found able to modulate expression of multidrug resistance related genes 
to reverse the cytotoxic effect of chemotherapeutic agents. Liu and coworkers demonstrated 
that CD133-posive BTSCs are significantly resistant to conventional chemotherapeutic 
agents including TMZ, carboplatin, paclitaxel and etoposide when compared to autologous 
CD133-negative GBM cells (Liu et al. 2006). Further real-time PCR analysis revealed that 
CD133-positive BTSCs have an enhanced gene expression of multi-drug resistance and 
DNA mismatch repair, as well as genes inhibiting apoptotic cascade. For instance, ATP-
binding cassette sub-family G member 2 (ABCG2), a gene accounting for chemoresistance of 
multiple cancer types, is increased 6.5 times in BTSCs than in CD133-negative cells. Of note, 
the expression of MGMT, a pivotal DNA repair enzyme that confers resistance to alkylating 
agents, in CD133-positive cells, is found 32.4 times as high as that in non-BTSCs. In addition, 
anti-apoptotic genes, including FLIP, BCL-2 and BCL-XL, are also found markedly up-
regulated while the expression of pro-apoptotic gene BAX is repressed in CD133-positive 
BTSCs. Hussein and coworkers established a panel of pediatric BTSC cell lines and analyzed 
their sensitivity to etoposide (Hussein et al. 2011). BTSCs are found to be enriched when 
they are maintained as neurospheres in serum-free medium supplemented with EGF and 
FGF compared to as monolayers in serum-containing FBS. The clonogenic survival analysis 
demonstrated that neurosphere-derived cells are significantly more resistant to etoposide. 
Two ATP-binding cassette multidrug transporters, ABCB1 and ABCC1, are enriched in 
CD133-positive BTSCs and are further increased by etoposide treatment. 
3.3 Resistance of BTSCs to immunotherapy 
Immunotherapy represents a promising strategy for the treatment of cancers in addition to 
conventional therapeutic approaches. The virtue of immunotherapy is that it mobilizes the 
patient’s immune system to specifically recognize and eradicate cancer cells while spares 
normal cells at the same time. The researches of immunotherapy against gliomas were once 
hindered by the perception that the brain is an immune privileged organ, basing on several 
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evidences. For example, the existence of blood-brain barrier (BBB) separates brain 
parenchyma from systemic circulation, which was assumed to hamper the entrance of 
immune effector cells into the brain (Pachter, de Vries, and Fabry 2003). In addition, the 
paucity of major histocompatibility complex (MHC) expression on brain cells, and the lack 
of organized lymphoid tissue and lymphatic drainage also suggest the difficulty to initiate 
effective immune responses (Read et al. 2003; Walker, Calzascia, and Dietrich 2002). 
However, several studies threw doubt on the assumption of the complete immunological 
silence in CNS. The findings in CNS autoimmune diseases including multiple sclerosis 
indicate the capability of activated T lymphocytes to traverse the BBB (De Simone et al. 
1995). In addition, BBB in patients with infection and tumour appears to be compromised 
(Avison et al. 2004; Davies 2002). Moreover, MHC antigens are found to be up-regulated at 
sites of brain injury, degenerative disease and tumour (Yang et al. 2006). All the 
observations mentioned above lead to intense interest in the application of immuotherapy 
against gliomas. However, until now, only limited clinical efficacy has been observed. 
Recent studies indicated that BTSCs employ various mechanisms of immune evasion. The 
generation of a successful classic specific immune response requires antigen uptake by 
antigen-presenting cells (APC) and subsequent activation of immune effector cells by APCs. 
Simply, APCs ingest antigenic peptides of target cells and then prime CD8+ (cytotoxic T 
cells, CTLs) for MHC class I and CD4+ (T-helper cells) for MHC class II, which will take 
effect to kill target cells (Sikorski and Lesniak 2005). BTSCs are found to express lower level 
of MHC than their differentiated counterpart in FBS medium. Since MHC I plays a critical 
role in the immune response, the altered MHC I expression shelters BTSCs from the 
recognition and subsequent lysis by CTLs (Di Tomaso et al. 2010). In addition to escaping 
immune response, BTSCs can profoundly influence the function of immune system 
components. BTSCs but not differentiated glioma cells are able to inhibit allogeneic T-cell 
proliferation. With enzyme-linked immunosorbent assay, Wei and coworkers found that 
BTSCs produce multiple immunosuppressive cytokines including transforming growth 
factor -β1 (TGF-β1) and prostaglandin E2 (PGE2) (Wei et al. 2010). TGF-β is a family 
comprising a large number of structurally related polypeptide growth factors and has been 
reported to be involved in immune response (Kirkbride and Blobe 2003). TGF-β inhibits the 
maturation and antigen presentation of APCs. As well, TGF-β has been found to inhibit T 
cell proliferation and activation. Moreover, TGF-β can impair CTL function through 
inhibiting the synthesis of cytotoxic molecules including FasL, IFN-γ and perforin. As for 
PGE2, it is a product of arachidonic acid metabolism, which is produced at sites of 
inflammation or tissue injure (Wang and Dubois 2006). PGE2 can suppress T cell activation 
and inhibit the anti-tumour activity of NK cells. Besides, PGE2 are shown to inhibit immune 
response through down-regulating the production of Th1 cytokines (IFN-γ and TNFα) and 
up-regulating Th2 cytokines (IL-4 and IL-10). PGE2 is also reported to enhance the 
suppressive activity of regulatory T cells. In addition, BTSCs are found to trigger T cell 
apoptosis mediated by co-stimulatory molecule B7-H1 and soluble Galectin-3. These 
findings suggested that BTSCs are able to escape immunotherapy through diminishing 
signals for immune recognition and inducing profound immune suppression. 
4. BTSCs, promising therapeutic target 
Although much effort has been made to aggressively treat malignant brain tumours, the 
prognosis is far from satisfactory. An accumulation of recent studies suggested the pivotal 
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role of BTSCs in the treatment resistance to conventional therapies. The current treatment 
strategies appear to effectively reduce the bulk of brain tumour cells but spare BTSCs. The 
improvement in the understanding of mechanisms underlying BTSC regulation provides 
insight into the development of novel treatment specifically targeting key signalling 
pathway and microenvironment of BTSCs, which appears to be a promising path leading to 
the cure of malignant brain tumours. 
4.1 PI3K/Akt signaling 
PI3K/Akt signaling is one of the most important and widely investigated pathways in brain 
tumours. As a major intracellular effector, PI3K transduces membrane-based activation from 
various sources, including G proteins such as Ras and receptor tyrosine kinases such as 
EGFR. Activation of PI3K/Akt pathway is implicated to regulate cellular proliferation, 
metabolism, differentiation and survival (Engelman, Luo, and Cantley 2006). Dysfunction of 
PI3K/Akt pathway is frequently observed in gliomas and suggested to mediate the 
gliomagenesis, progression and the resistance to therapy, which can be resulted from 
persistent activating signals from cell membrane (i. e. EGFR mutations), gain-of-function 
mutations in PI3K components (i. e. PIK3CA) and loss of tumour suppressor (i. e. PTEN 
deletion). In fact, PI3K-activating mutations are detected in almost all patients with GBMs 
(Comprehensive genomic characterization defines human glioblastoma genes and core 
pathways 2008, ; Parsons et al. 2008). Recently, PI3K/Akt pathway has been reported to be 
essential for the survival and treatment resistance of BTSCs. An animal model study 
demonstrated that the activation of PI3K/Akt pathway due to the loss of PTEN in gliomas 
greatly increases the SP cells and renders them to be more resistant to multiple 
chemotherapeutic agents including TMZ (Bleau et al. 2009). In addition, activated PI3K/Akt 
pathway protects BTSCs in their niche from radiation-induced apoptosis through the 
induction of p53-dependent cell cycle arrest (Hambardzumyan et al. 2008). Based on the 
critical role in BTSC biology, activated PI3K/Akt pathway can be a promising target against 
BTSCs. Eyler and coworkers revealed that BTSCs isolated from primary GBMs are more 
sensitive to Akt inhibition. Treatment with an Akt inhibitor resulted in a more remarkable 
reduction of BTSCs compared with non-BTSCs, which is associated with a preferential 
induction of apoptosis and a suppression of neurosphere formation. Furthermore, inhibition 
of Akt activity impairs the tumourigenicity of BTSCs and significantly prolongs the survival 
of mice bearing glioma xenografts initiated by BTSCs (Eyler et al. 2008). In another study 
performed by Sunayama and coworkers, dual blockade of PI3K and mTOR has a profound 
effect on BTSCs. Exposure to LY294002 combined with NVP-BEZ235 disrupts the self-
renewal and triggers differentiation in BTSCs, with an inhibition of neurosphere formation 
and tumour initiation, as well as an up-regulation of neuronal differentiation marker, βIII-
tubulin (Sunayama et al. 2010). 
4.2 STAT3 
Signal Transducer and Activator of Transcription 3 (STAT3) is a potentially attractive 
therapeutic target for BTSCs based on its dual role in regulation of stem cell functions and 
oncogenesis. STAT3 belongs to a family of latent transcription factors that are activated by 
multiple extracellular and intracellular signals including the Janus kinase (JAK) family and 
receptor tyrosine kinases (RTKs) (Darnell 1997). After phosphorylation of a tyrosine residue 
in the transactivation domain, activated STAT proteins dimerize, translocate into the 
nucleus and modulate gene expression by binding to specific DNA-response elements in the 
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promoter of target genes, including genes associated with cell survival, cell cycle regulation, 
immune response and differentiation, such as c-myc, cyclin D1, Bcl-2, VEGF and HIF1α. 
STAT3 is a crucial component in the regulation of embryonic development and the 
maintenance of multiple normal stem cell types, with mouse models demonstrating that 
STAT3-deficiency leads to lethality at E6.5 (Takeda et al. 1997). In neural development, 
STAT3 is necessary for the maintenance and self-renewal of neural stem cells and precursors 
(Yoshimatsu et al. 2006). In addition, STAT3 is an oncogene that induces transformation 
through increased expression of target genes that promote cell growth and inhibit apoptosis 
in multiple cell types. Constitutive activation of STAT3 is observed in a variety of tumours 
including glioma (Rahaman et al. 2002). STAT3 is found to be a master regulator of 
mesenchymal transformation in gliomas and correlate with poor prognosis of glioma 
patients. Elimination of STAT3 and another transcriptional factor C/EBPbeta leads to the 
collapse of the mesenchymal signature and reduces tumour aggressiveness (Carro et al. 
2010). STAT3 has been identified as an important maintenance factor for BTSCs. Under 
undifferentiated condition, BTSCs have a constitutively high level of phosphorylated 
STAT3. Genetic knockdown of STAT3 leads to a significant inhibition of proliferation and 
neurosphere formation of BTSCs. Of note, even a transient inhibition of STAT3 is sufficient 
to result in irreversible growth arrest and diminishment of neurosphere formation, implying 
the critical role of STAT3 in the maintenance of BTSC self-renewal (Sherry et al. 2009). In 
addition, an inhibition of STAT3 synergizes the anti-cancer effect of TMZ against BTSCs and 
impairs the tumourigenic capacity of BTSCs in vivo (Villalva et al. 2011; Li et al. 2010). 
4.3 Differentiation induction in BTSCs 
Normal neural stem cells are characterized with their multipotency to differentiate into 
neurons, astrocytes and oligodendrocytes. BTSCs, although aberrantly, can also differentiate 
into tumour progenies with multi-lineage morphologies and markers. These differentiated 
cells constitute the bulk of brain tumours but lose the capacity of unlimited proliferation  
in vitro and the tumourigenicity in vivo. Therefore, exhaustion of BTSC pool by the induction 
of differentiation appears to be a practical therapeutic strategy. In fact, differentiation-
inducing agents have already been used in the management of brain tumours before the 
surge of BTSC theory. The clinical activity of retinoids, known as powerful modulators of 
cellular differentiation and proliferation, was evaluated in patients with recurrent malignant 
brain tumours. In a Phase II study performed by Yung and coworkers, high-dose  
13-cis-retinoic acid (CRA) is found to be effective against malignant gliomas with acceptable 
toxicity. CRA appears to work as a cytostatic rather than a cytolytic agent. The mechanism 
underlying the antitumour activity of CRA was not clearly known at that time (Yung et al. 
1996). But now, under the BTSC scenario, this effect of CRA is attributed to its ability to 
induce differentiation in BTSCs. Exposure to all-trans-retinoic acid (ATRA) decreases  
CD133 level and results in an augmented expression of lineage markers in BTSCs. The 
disruption of angiogenesis and impairment of motility are also observed in BTSCs after 
ATRA treatment. In addition, the differentiation induced by ATRA can sensitize BTSCs to 
chemotherapy and irradiation by increasing cell death and apoptotic susceptibility (Campos 
et al. 2010).  
Key components in several signalling pathways have been identified to be involved in the 
differentiation induction of BTSCs. Bone morphogenetic proteins (BMPs) belong to the 
transforming growth factor-β superfamily and play an important role in promoting 
differentiation in embryonic stem cells and neural stem cells. BMPs are also assessed for the 
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differentiation induction in BTSCs. Piccirillo and coworkers demonstrated that non-
cytotoxic BMP4 starts the differentiation program in BTSCs, resulting in a depletion of BTSC 
pool by 50% and an induction of morphological transition into more committed tumour 
cells. BTSCs transiently pre-treated with BMP4 fail to initiate large invasive and highly 
vascular tumour masses in vivo but only generate small lesion with low capacity of 
proliferation and infiltration. In addition, intracranial delivery of BMP4 simultaneously or 
10 days after the injection of BTSCs into mouse brain retards tumour growth and prolongs 
the survival of tumour-bearing mice (Piccirillo et al., 2006). This study presents 
differentiation induced by BMPs as a promising strategy to target BTSCs. However, 
subsequent investigations demonstrated that not all BTSCs are readily responsive to BMPs 
at all time. Induction of differentiation in BTSCs by BMPs can be blocked by intrinsic and 
extrinsic factors. The response of BTSCs to BMPs depends on the expression and normal 
function of BMP receptors. In a subset of BTSCs, the expression of BMP receptor 1B 
(BMPR1B) is lost due to epigenetic silencing by an EZH2-dependent mechanism (Lee et al. 
2008). In addition, the differentiative effects of BMPs on BTSCs can be regulated by oxygen 
tension. A hypoxic condition renders BTSCs to be more resistant to BMP-induced 
differentiation, which is found to be mediated by HIF1α (Pistollato et al. 2009).  
Notch, a modulator of neural stem cell fate, has also been demonstrated to play a key role in 
the differentiation of BTSCs. Notch proteins are cell surface receptors that mediate cell-cell 
communication. After binding with transmembrane ligands from adjacent cells, Notch releases 
its intracellular domain cleaved by γ-secretase. The intracellular domain then translocates 
into the nucleus and functions as a transcription factor to regulate target gene expression. In 
the embryonic central nervous system, Notch signalling maintains a pool of undifferentiated 
neural stem cells by promoting the proliferation while inhibiting their differentiation into 
neurons. The dysregulation of Notch signalling pathway has been reported in a variety of 
neoplasms, including breast cancer, leukemia, and melanoma. In brain tumours, increased 
expression of Notch-related genes and elevated Notch activities are also found. Gene 
expression array demonstrated that Notch ligand Jagged-1, Notch 3 and the downstream 
target of Notch (HES1 and HES2) are overexpressed in a majority of primary GBMs relative 
to non-neoplastic brain tissues (Kanamori et al. 2007). Purow and coworkers performed a 
detailed functional study on Notch signalling pathway in gliomas. In this study, the presence 
of Notch-1 was found in glioma tissues and six glioma cell lines. Down-regulation of Notch-
1 with siRNA leads to decreased cell proliferation, cell cycle arrest and apoptosis in glioma 
cells. Knock-down of Notch-1 significantly prolongs the survival of mice orthotopically 
transplanted with glioma cells (Purow et al. 2005). Moreover, Notch signalling is also linked 
to the maintenance and differentiation of BTSCs. When investigating GBM BTSCs, Fan and 
coworkers found that BTSCs derived from GBMs are sensitive to Notch signalling blockade 
by γ-secretase inhibitors (GSIs). GSIs selectively reduce the proliferation of Nestin- or 
CD133-positive BTSCs, which results in an inhibition of neurosphere clonogenicity in vitro 
and tumourigenicity in vivo (Fan et al. 2010). In another study carried by the same group, 
Notch blockade is found to preferentially target BTSCs in medulloblastomas. GSI exposure 
reduces the CD133-positive cell fraction by almost 5-fold and totally depletes the side 
population cells. The viable cells after the GSI treatment have an increased expression of two 
neuronal markers, Tuj1 and GABRA6. These better-differentiated tumour cells can continue 
to proliferate but fail to establish soft-agar colonies or tumour xenografts (Fan et al. 2006). 
These studies indicate that Notch blockade can induce differentiation in BTSC and can be 
potentially useful in the treatment of malignant brain tumours. 
www.intechopen.com
 
Cancer Stem Cells - The Cutting Edge 
 
260 
4.4 BTSC niche 
It has been recognized that stem cells are not randomly distributed throughout the organ 
where they remain. In fact, stem cells reside in niche, a specific microenvironment consisted 
of both cellular and acellular components, which plays an important role in regulating the 
function of stem cells (Burness and Sipkins 2010). In the brain, neural stem cells (NSC) are 
concentrated in the subgranular zone of the hippocampus and the subventricular zone of 
the lateral ventricle, with close proximity to blood vessels (Quinones-Hinojosa et al. 2007). 
The contact and communication of niche and NSCs are critical in maintaining the quiescence 
and driving the proliferation and differentiation of NSCs. BTSCs are proposed to origin 
from the oncogenic transformation of NSCs and appear to occupy similar niches. The 
subventricular zone has long been proposed as the source of glioma, based on the 
observation that many gliomas either grow around the ventricle or are contiguous with the 
subventricular zone (Glantz et al. 2009). In clinical studies, bordering lateral ventricle by 
gliomas has been associated with decreased survival. Chaichana and coworkers analyzed 
the relationship of the tumour location and the survival of GBM patients (Chaichana et al. 
2008). The authors found that GBM patients with a radiological contrast-enhancing lesion 
bordering the lateral ventricles (LV CEL) have a more unfavourable prognosis compared to 
patients with non-LV CEL and therefore postulated that the region of lateral ventricles may 
have a microenvironment more conducive for potent tumour cells, perhaps BTSCs, to 
proliferate and/or infiltrate. This area also has been shown to have an increased propensity 
to form glioma in animal studies. Marumoto and coworkers successfully induced 
intracranial high-grade gliomas in adult immunocompetent mice by injecting Cre-loxP-
controlled lentiviral vetors expressing oncogenes (Marumoto et al. 2009). Of note, more than 
75% of mice show tumour formation when viral vectors are injected in neurogenic areas 
such as the subventricular zone and hippocampus, while there is little tumour formation in 
the cortex. Moreover, transplantation of these brain tumour cells into naïve recipient mouse 
brain results in the formation of GBM-like tumours containing BTSCs. This study suggested 
the susceptibility of cells in neurogenic areas to oncogenic stimuli and the possible origin of 
BTSCs in these areas. 
Malignant gliomas are characterized as highly vascular tumours. The presence of 
microvascular proliferating structures is recognized as a pathological criterion in diagnosis 
of high-grade gliomas. The density of microvascular proliferation has been demonstrated to 
correlate with the prognosis of glioma patients (Wong et al. 2009). Accumulating evidence 
suggested that vasculatures in glioma are more than pipelines to supply nutrients and 
oxygen, they can function as niches, interacting with brain tumours and regulating BTSC 
behaviour (Gilbertson and Rich 2007). A dynamic analysis revealed that gliomas cells 
extensively infiltrate the brain parenchyma through migrating along blood vessels. 
Remarkably, the majority of glioma cells divide around vascular branch points, indicating 
that the microenvironment provides cues to trigger mitosis (Farin et al. 2006). Calabrese and 
coworkers did the first thorough investigation on the perivascular niche for BTSCs. With 3-
dimensional (3D) imaging, the authors clearly demonstrated that Nestin-positive BTSCs 
directly associate with tumour capillaries in glioma specimens. Coculture with primary 
human endothelial cells (PHECs) maintains the self-renewing and undifferentiated status of 
BTSCs. Moreover, PHECs are found to robustly expand the proliferation of BTSCs and 
promote tumour growth in vivo. It is suggested that vascular endothelial cells may support 
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Because BTSCs have intimate relationship with their microenvironment, targeting the niche 
seems to be a desirable therapeutic strategy to eradicate BTSCs. Increasing the dosage of 
irradiation to BTSC niche has been shown to yield significant benefits for patients with high-
grade gliomas. Evers and coworkers performed a retrospective analysis to investigate the 
effect of the radiation to the periventricular niche on the prognosis of 55 adult patients with 
malignant glioma (Evers et al. 2010). The progression-free survival of patients whose 
bilateral subventricular zone (SVZ) received greater than the median SVZ dose (43 Gy) is 
15.0 months, which is much longer than that (7.2 months) of patients who received less than 
the median dose. Besides, disruption of the vascular structures that BTSCs depend on is also 
a promising option. Preclinically, anti-angiogenic agents are shown to specifically act on 
BTSCs (Calabrese et al. 2007). Erlotinib and Bevacizumab are successful in inhibiting the 
self-renewasl of BTSCs and suppressing the tumour growth in glioma-bearing mice, 
implying the efficacy of the disruption of BTSC niche. Similarly, Williams and coworkers 
revealed that creation of a barrier between BTSCs and endothelial cells can decrease the 
number of BTSCs in glioma xenografts (Williams et al. 2010). The authors treated the 
orthotopic glioma models with IFN-β. Although IFN-β is not directly toxic to BTSCs in vitro, 
treatment with IFN-β leads to tumour growth arrest in vivo by affecting the BTSC niche. 
IFN-β increases perivascular cells investing vasculature, resulting in the disruption of the 
communication between BTSCs and endothelial cells. Clinically, bevacizumab, a monoclonal 
antibody targeted against VEGF, and cediranib, a small molecule inhibitor of VEGF show 
some success. After a systematic review and survival-gain analysis, Xu and coworkers 
found that combination of bevacizumab and irinotecan largely improves response rates and 
has a possible moderate effect on overall survival in patients with recurrent adult high-
grade glioma (Xu et al. 2010). A Phase II clinical trial performed by Batchelor and coworkers 
demonstrated that treatment for recurrent GBM with Cediranib monotherapy results in 
encouraging proportions of radiographic response and 6-month progression-free survival 
(Batchelor et al. 2010). In addition to depletion of the tumour blood supply, the clinical 
efficacy of anti-angiogenic drugs may be partly attributed to the disruption of the 
perivascular niche of BTSCs (Gilbertson and Rich 2007). 
5. Future directions and challenges 
The emergence and evolution of BTSC concept broaden our horizon in the understanding of 
brain tumour biology. The roles of BTSCs in the progression and treatment resistance of 
brain tumours lead us to have a reassessment of the current treatments. Key signalling 
pathways identified in BTSCs provide clues to develop novel therapeutics, which may pave 
the road to the cure of malignant brain tumours. However, this road can be winding and 
bumpy. There are still challenges we should realize. First, BTSCs are heterogeneous and the 
markers as well as approaches to purify BTSCs currently employed are unlikely to identify 
all BTSC phenotypes. New markers need to be explored and a combined use of a set of 
various markers and/or purification techniques appears to be more effective in the 
identification of different BTSC population. Secondly, many signalling pathways pivotal to 
the maintenance and self-renewal of BTSCs are also necessary for normal stem cells. 
Approaches aiming at these signalling pathways may do harm to normal stem cells. 
Therefore, critical signalling pathways specific in BTSCs are superior targets. Thirdly, the 
stemness of BTSCs is not unchangeable, which can be tuned in order to adapt tumour cells 
to the changes in microenvironment. Therefore, BTSCs appear to be running targets instead 
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of stationary ones. The therapeutic strategies against BTSCs should be continuously 
modulated. Finally, the microenvironment contributes significantly to the phenotype and 
plasticity of BTSCs. The effective treatment in future should focus on not only BTSCs per se 
but also the niches BTSCs reside in.  
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